Teleflex Announces the Teleflex Center for Antimicrobial Protection

/EIN News/ -- WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives.

The Teleflex Center for Antimicrobial Protection, located in Research Triangle, North Carolina, is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. Too often patients are exposed to these “superbugs” which can lead to additional complications and an increased length of stay in a hospital setting.¹ Through education and partnership with professionals in infection prevention, TCAP seeks to be a resource for patients, physicians, and healthcare organizations.

“Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients by helping to reduce vascular access related complications,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are proud of TCAP’s commitment to antimicrobial catheter technology and our ability to reduce the colonization of major pathogens linked to central line associated blood stream infections (CLABSI).”²

The Teleflex Center for Antimicrobial Protection aims to provide quality products, services, and education to its customers by pioneering catheter protection technology and developing innovative vascular access devices.

TCAP recently sponsored an educational webinar focused on the expansion of surveillance of healthcare-acquired infections (HAI), specifically central line-associated bloodstream infections (CLABSI). That webinar can be viewed on-demand through Teleflex Academy.

Teleflex, through its Arrow™ Brand of Vascular Access Products, has the only comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against gram-positive, gram-negative, and fungal pathogens.^2,3,4 Additionally, Arrow™ Maximal Barrier Kitting options provide protection for patients and improve procedural efficiency for clinicians.⁵ This portfolio of products was showcased at the Association for Professionals in Infection Control and Epidemiology (APIC) 2024 Annual Conference. During the conference, TCAP sponsored an educational Exhibitor Theater session, focused on CLABSI trends. To learn more about Arrow™ Antimicrobial Catheter and Kitting Solutions, visit our website.

About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2024 Teleflex Incorporated. All rights reserved. MC-009780

References:

1. Toor H, Farr S, Savla P, Kashyap S, Wang S, Miulli DE. Prevalence of central line-associated bloodstream infections (CLABSI) in intensive care and medical-surgical units. Cureus. 2022;14(3):e22809.doi:10.7759/cureus.22809
2. In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.
3. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of Central Venous Catheter-Related Bloodstream Infection With an 'Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial. Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.
4. Spangler D and Moss S. In-Vitro Assessment of Antimicrobial Activity of Three Commercially Available Central Venous Catheters. Poster by Arrow (Teleflex) International, Inc. Department of Applied Research. 2010-0406 v1
5. Fenik Y, Celebi N, Wagner R, et al. Prepackaged central line kits reduce procedural mistakes during central line insertion: a randomized controlled prospective trial. BMC Medical Education. 2013;13:60. Published 2013 Apr 30. doi:10.1186/1472-6920-13-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645964/
   

Rx only

Contraindications:

The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa drugs.

Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ Catheters are contraindicated in the following areas:

• Patients with known hypersensitivity to chlorhexidine
• In presence of device related infections
• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.

No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert.

Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836